MET is clinically validated target in several cancer types. MET operates just downstream to the famous P53. Addiction of cancers like breast and lung to MET as well as its absence from healthy adult tissues makes it a highly desirable target. Existing anti-MET marketed drugs (crizotinib & ...
1586128566.jpg)